Clinical Trials Logo

Clinical Trial Summary

This study will evaluate members in families with a history of small bowel carcinoid cancer to study the natural history of those family members that have the disease, determine ways to improve early detection by performing surveillance on those at risk but without disease and to identify the gene(s) that may cause the tumors. Familial carcinoid tumors usually originate in hormone-producing cells that line the small intestine or other cells of the digestive tract. The tumors are slow-growing and usually take many years before they cause symptoms. It is known that these tumors occur more often in some families and are then passed from one generation to the next by inherited genes. Members of families, including all siblings and offspring in which two or more immediate blood relatives have had small bowel carcinoid tumors are eligible for this study. In some cases unaffected spouses of family members diagnosed with carcinoid cancer are also requested to participate by donating a sample of blood only. Participants undergo a medical evaluation every 3 years during a 3- to 5-day hospital stay at the NIH Clinical Center. All participants have a personal and family medical history obtained and undergo a physical examination, blood and urine tests. People who already have a small bowel carcinoid tumor or are at risk of developing a carcinoid tumor have some or all of the following procedures to determine the presence of carcinoid tumor and its (omit next two words- location or) spread to other areas of the body: - Video Capsule Endoscopy: Visualization of the gastrointestinal tract by ingesting a disposable, "vitamin-pill sized" video capsule that has its own camera and light source. - CT of the chest abdomen and pelvis with oral and IV contrast : X-ray examination of the chest, abdominal and pelvis organs. - 18 FDOPA Positron emission tomography (PET) with CT for localization: Nuclear imaging scan to look at tumor activity. - MRI Liver with contrast - to determine if disease has spread to liver - Gallium 68 PET/CT-limited to individuals that have residual tumor. - Clinical and research blood work Should mid gut carcinoid tumors be found every participant will be assisted in determine what the best course of treatment will be for them.


Clinical Trial Description

Study Description: This study is designed as a prospective evaluation for diagnostic screening, genotyping and natural history of participants belonging to kindreds with familial carcinoid tumor. Objectives: Primary Objective: Study the natural history of familial carcinoid tumors: incidence, age of onset, symptoms, the appropriate diagnostic (biochemical and imaging) modalities, location, histology and metastatic potential of the tumors, metabolic sequelae of the tumor, and clinical and biochemical prognostic factors. Secondary Objectives: - Screen for occult disease and determine whether early detection affects the natural history of the disease. - Compare the sensitivity and specificity of various imaging tomography (CT) with IV contrast and oral Volumen, 18FDOPA PET/CT scan, [68Ga] DOTATATE PET/CT scan and endoscopic modalities for diagnosing and following carcinoid tumors. - Collect tumor specimens for histologic evaluation, culturing of intestinal organoids, and genotyping (including DNA and RNA sequencing). - Sequester DNA from peripheral blood for genotyping (including sequencing) with the intention of localizing a susceptibility gene/s responsible for the familial occurrence of the disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00646022
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Joanne Forbes, C.R.N.P.
Phone (301) 443-9557
Email forbesjo@mail.nih.gov
Status Recruiting
Phase
Start date August 25, 2008

See also
  Status Clinical Trial Phase
Completed NCT01327612 - Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Phase 2
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Not yet recruiting NCT02038738 - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT01322542 - YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome Phase 2
Withdrawn NCT03623984 - Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers Early Phase 1
Completed NCT00339131 - ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Phase 1
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Completed NCT00050349 - EPO906 in Carcinoid and Other Neuroendocrine Tumors Phase 2
Terminated NCT01165658 - Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Phase 1
Recruiting NCT03583528 - DOTATOC PET/CT for Imaging NET Patients
Enrolling by invitation NCT02270567 - RegisterNET - A Registry for Neuroendocrine Tumors in the USA
Active, not recruiting NCT00314925 - Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features Phase 1